Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial.

Blood · 2023 · PMC10651777 · PMID 36265087

Europe PMC DOI

hedged sentence

0.0900

closest p · 1.8× alpha

0.0900

boldest claim

The sentences

showed a trendP = .09so close (0.05 < p ≤ 0.1)

Achievement of partial response/MLFS showed a trend toward improved median OS vs nonresponders (5.7 vs 3.0 months, respectively, P = .09).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.